Genelux Corporation Profile Avatar - Palmy Investing

Genelux Corporation

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-…

Biotechnology
US, Westlake Village [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Genelux Corporation mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of GNLX's Analysis
CIK: 1231457 CUSIP: - ISIN: US36870H1032 LEI: - UEI: -
Secondary Listings
GNLX has no secondary listings inside our databases.